Company news
4d Molecular Therapeutics, Inc. (NASDAQ:FDMT) news
4d Molecular Therapeutics, Inc. news releases on 6ix. Latest, Oct 5, 2026: 4DMT to Host Investor Day on October 21, 2026
Press releases & updates
4DMT to Host Investor Day on October 21, 2026
October 4, 2026
4DMT to Host Investor Day on October 21, 2026
October 5, 2026
4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME
September 28, 2026
4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
August 13, 2026
4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population
July 18, 2026
4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists
June 30, 2026
4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital
June 29, 2026
4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD
June 29, 2026
4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
May 7, 2026
4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
March 17, 2026
4DMT to Participate in Upcoming Investor Meetings
March 16, 2026
4DMT Announces New Employment Inducement Grants
February 13, 2026
4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD
February 9, 2026
4DMT Provides Company Update and Anticipated Development Milestones for 2026
January 7, 2026
4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease
December 17, 2025
4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 8, 2025
4DMT to Participate in 8th Annual Evercore Healthcare Conference
November 20, 2025
4DMT Appoints Kristian Humer as Chief Financial Officer
November 17, 2025
4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
November 10, 2025
4DMT to Participate in Jefferies 2025 London Healthcare Conference
November 6, 2025
4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants
November 6, 2025
4DMT Announces Positive Long-Term Data from Phase 1/2 PRISM Clinical Trial in Wet AMD Supporting 4D-150’s Potential as a Backbone Therapy with Consistent and Durable Benefit over Multiple Years
November 6, 2025
4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific
October 29, 2025
4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference
October 14, 2025
4DMT Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation
October 13, 2025
4DMT Announces Leadership Expansion with Proven Late-Stage Executives to Drive 4D-150 Execution and BLA Readiness
September 2, 2025
4DMT to Participate in Upcoming Investor Conferences
August 25, 2025
4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
August 11, 2025
4DMT to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
August 6, 2025
4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update
July 31, 2025
4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists
July 24, 2025
BBOT Appoints Industry Veteran Uneek Mehra as Chief Financial Officer
July 21, 2025
4DMT Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage Execution
July 2, 2025
4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
May 8, 2025
4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME
May 1, 2025
4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD
March 10, 2025
4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
February 28, 2025
4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program
February 7, 2025
4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population
January 28, 2025
4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway
January 9, 2025
4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path
January 9, 2025
4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS
December 15, 2024
4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV
November 13, 2024
4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
November 12, 2024
4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference
September 22, 2024
4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day
September 17, 2024
4DMT Announces Presentations at Upcoming Retina Conferences
September 4, 2024
4DMT to Participate in the 2024 Cantor Global Healthcare Conference
September 2, 2024
4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024
August 26, 2024
4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
August 11, 2024